Doctors prescribing selective serotonin reuptake inhibitors (SSRIs) to patients with depression and anxiety should warn them first of the risks associated with stopping the treatment, the Medicines and Healthcare Products Regulatory Agency (MHRA) has advised, after receiving recommendations from an expert group convened by the Committee on Safety of Medicines. Doctors should also monitor closely patients starting to use the drugs.
But the expert group found no evidence of more suicidal thoughts or tendencies among adults prescribed the drug than among those taking placebo or older tricyclic drugs. This is despite the fact that the potential harmful effects of the drug in children are now widely recognised. The MHRA has issued warnings about the risk of self harm and suicidal thoughts in young people taking the drugs (BMJ 2004; 328:3-4) and the Food and Drugs Administration in the United States has also heard reports of similar concerns (BMJ 2004; 329:641, 18 Sep) .
The yellow card system, a mechanism in the United Kingdom for reporting adverse reactions, had indicated that there might be similar effects in adults.
The expert working group concluded, "From the available clinical trial data, both published and unpublished, a modest increase in the risk of suicidal thoughts and self harm for SSRIs compared with placebo cannot be ruled out."
It added that, compared with other antidepressants, "there is insufficient evidence from clinical trial data to conclude that there is any marked difference between members of the class of SSRIs or between SSRIs and other antidepressants with respect to their influence on suicidal behaviour."
"The number of patients in the trials is not sufficient [to provide] confidence intervals," said Kent Woods, chief executive of the MHRA. He added that, although the yellow card system could "generate a signal of the nature of the problem," it "cannot give you an indication of how common that problem is."
The expert group also warned that, given the concern about the use of SSRIs by children and adolescents, it is important for doctors to monitor closely young adults up to the age of 30.
It has also issued a warning that the serotonin and noradrenaline reuptake inhibitor venlafaxine should be prescribed only by psychiatrists and other medical practitioners with a special interest in mental health.
The expert group began its investigation in May 2003. According to Professor Woods, the committee looked at the results of 600 randomised controlled trials; the GP research database, which covered 146 000 patients; and spontaneous reports of suspected adverse reactions.
The The BMJ has been given a set of documents that mysteriously went missing from a US mass murder case 10 years ago. The killer was taking a selective serotonin reuptake inhibitor at the time of the murders.
The internal drug company documents marked "Confidential," which were sent to the BMJ by an anonymous source, indicate a link between a selective serotonin reuptake inhibitor and a side effect, known as the "activation syndrome," which includes agitation, mania, and hostility.
The BMJ has offered to turn the documents over to officials of the Food and Drug Administration, but no one at the FDA was available to comment as the BMJ went to press. The documents were sent to the BMJ as a federal circuit court judge ruled on 3 December that Pfizer must turn over internal research documents to the defence counsel for a boy charged with murdering his grandparents.
Christopher Pittman, aged 12 at the time of the killings, confessed that in November 2001 he used a shotgun to shoot first his grandfather and then his grandmother as they slept. He then set fire to the home and fled in the family car. He is to be tried as an adult and has been in prison for the past three years awaiting trial. He faces life imprisonment.
Several weeks before the killings he was started on the antidepressant sertraline, and his dose was doubled just two days before the killings.
The FDA recently sent a letter to drug companies with a template to use for warning about the dangers of antidepressants in children. The effects listed by the FDA included agitation, panic attacks, irritability, hostility, impulsivity, akathisia, and mania.
A Pfizer spokesman, Bryant Haskins, said that both Pfizer and the FDA opposed efforts to make the documents public because they "contain anecdotal information" that is "not relevant to this case," according to an article in the 3 December issue of the Herald of Rock Hill, South Carolina (www.heraldonline.com/).
The FDA told the BMJ that it could not comment on cases involving pending litigation.
One of Christopher Pittman's attorneys, Karen Barth Menzies of Los Angeles, told the BMJ that Pfizer's documents were important because they showed that some of Pfizer's own scientists had expressed concern that sertraline could cause violence.
Peter Breggin, a psychiatrist who served as the scientific expert in a review of over 100 cases of murder and suicide allegedly related to the antidepressant fluoxetine (Prozac), told the BMJ that the newer selective serotonin reuptake inhibitors cause an "activation syndrome" that is similar to the effect of amphetamines and that their dangers are akin to the dangers of street drugs. "Why do we think that simply because a doctor prescribes a medication they lose their dangerous effects?" he said. 
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Christopher Pittman, aged 15, started taking sertraline several weeks before killing his grandparents. A judge has ruled that Pfizer must hand over documents about the drug to the boy's lawyer
